fulvestrant oral (VER001) / Veramorph - LARVOL DELTA

VeraMorph Completes Positive Pre-IND Meeting on Oral Fulvestrant Product, Receives NIH SBIR Phase II Grant (Businesswire) - "Positive pre-IND meeting with the FDA in regard to the regulatory pathway...the FDA conveyed openness to the proposed clinical strategy...VeraMorph has received a $2.1M NIH SBIR Phase II grant...These studies will enable VeraMorph to bring oral fulvestrant into the clinic in 2027."

FDA event • Grant • Solid Tumor